Table 1.

Liposomal nanoparticle used in the treatment of asthma.

Author	Drug	Developmental Stage	Average Particle Size	Findings	Ref.
Honmane, et al.	Salbutamol sulfate	In vitro	167.2  ±  0.170 nm	The novel liposomal formulation might be a helpful alternative to traditional treatments	[31]
Arafa, et al.	Salbutamol sulfate	Phase I	400–451 nm	The entrapping drugs in niosomes, which can be bundled into aerosols meeting USP rules, is a promising option for developing a controlled drug delivery system.	[33]
Chen, et al.	Salbutamol sulfate	Preclinical studies	57 ± 21 nm	Liposomes increased salbutamol sulfate concentration and retention duration, and hence prolonged salbutamol therapeutic impact on asthma patients.	[35]
Elhissi, et al.	Salbutamol sulphate and Beclometasonedipropionate	In vitro	100–136 nm	The freeze-dried liposomes containing two anti-asthma medicines could be produced and may be used in pulmonary delivery.	[44]
Konduri, et al.	Budesonide	Preclinical studies		Minimize toxicity and increase compliance in asthma patients.	[37]
Ng, et al.	Curcumin	In vitro	271.3 ± 3.06 nm	Liposomal curcumin may be a viable asthma therapeutic strategy because of its ability to decrease key asthma pathogenesis pro-inflammatory signals.	[38]
Alberca-Custodio, et al.	Allergens and CpG	Preclinical studies		To treat eosinophilic (high type 2) asthma endotype, immunotherapy liposomal delivery method may be of benefit, and this may point to the critical role played by dendritic cells expressing Myd88 in the process.	[39]
Raju, et al.	Mesalamine	In vitro	200 nm	Mesalamine-loaded liposomes in disease-responsive microgels effective in asthmatic treatment.	[40]
Alvarez, et al.	D. pteronyssinus	Clinical studies		Extensive D. Pteronyssinus immunisation with liposome-entrapped mites protects moderate asthma patients against protracted mite exposure and lowers allergen-related functional and inflammatory alterations.	[41]
Li, et al.	R-terbutaline hydrochloride	Preclinical Studies	145 ± 20 nm	The R-terbutaline hydrochloride liposome group exhibited a longer anti-asthma effect than the R-terbutaline hydrochloride solution group	[42]
Arora, et al.	Doxophylline	In vitro	212.9 + 7.2 nm	Better retained in the liposomal formulation than in the controlled release formulation.	[43]